- Nivolumab as second-line therapy for patients with advanced NSCLC (non-small cell lung cancer)2022 | First Faculty of Medicine
- Complete response to pembrolizumab in a patient with stage IV NSCLC (non-small cell lung cancer)2020 | First Faculty of Medicine
- NSCLC (Non-Small Cell Lung Cancer) and kidney tumor in the elderly patient with response to chemoimmunotherapy2021 | First Faculty of Medicine
- Role of histology in the choice of treatment for advanced non-small-cell lung cancer2010 | Publication without faculty affiliation
- The role of durvalumab in the treatment of stage III NSCLC2020 | First Faculty of Medicine
- Pacient s generalizovaným nemalobuněčným karcinomem plic s fúzí ROS1 s výbornou klinickou i zobrazovací odpovědí na léčbě entrektinibem2021 | Publication without faculty affiliation
- Ground-breaking ADAURA trial - osimertinib as adjuvant therapy of EGFR-mutated NSCLC2022 | First Faculty of Medicine
- Cemiplimab: monotherapy and combination therapy of NSCLC - analysis of locally advanced disease2023 | First Faculty of Medicine
- Crizotinib in the treatment of generalized non-small-cell lung cancer - a case report2017 | Publication without faculty affiliation
- Lung adenocarcinoma with two simultaneous driving mutations2013 | Faculty of Medicine in Pilsen
- Immunotherapy in lung cancer treatment2016 | Publication without faculty affiliation
- Patient with NSCLC and brain metastases and positive reassortment ALK treated with alectinib - case report2020 | Publication without faculty affiliation
- Tumor Rebiopsy - Guide to Targeted Therapy2016 | Faculty of Medicine in Pilsen
- CCL2, CCL8, CXCL12 chemokines in resectable non-small cell lung cancer (NSCLC)2023 | First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University